Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating Expenses    
Research and development expenses $ 5,799,518 $ 11,494,230
General and administrative expenses 5,657,543 8,763,058
Impairment of intangible asset 7,268,143
Operating Loss (11,457,061) (27,525,431)
Other Income (Expense)    
Interest income, net 335,541 101,202
Net Operating Loss Before Income Tax Benefit (11,121,520) (27,424,229)
Income Tax Benefit
Net Loss $ (11,121,520) $ (27,424,229)
Net Loss Per Common Share - Basic $ (8.48) $ (34.05)
Net Loss Per Common Share - Diluted $ (8.48) $ (34.05)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic 1,311,572 805,477
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted 1,311,572 805,477